Teicoplanin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Teicoplanin" in English language version.

refsWebsite

Global rank English rank

36nih.gov

4^th place

26doi.org

2^nd place

7semanticscholar.org

11^th place

8^th place

2harvard.edu

18^th place

17^th place

1tga.gov.au

3,984^th place

2,622^nd place

1europa.eu

68^th place

117^th place

1toku-e.com

low place

1sciencedirect.com

149^th place

178^th place

1web.archive.org

1^st place

1chemsoc.org

low place

1atcc.org

low place

atcc.org

"Actinoplanes teichomyceticus Parenti et al". ATCC (American Type Culture Collection).

chemsoc.org

Gilpin M, Milner P (1997). "Resisting changes -- Over the past 40 years the glycopeptide antibiotics have played a crucial role in treating bacterial infections. But how long can it continue?". Royal Society of Chemistry. Archived from the original on 2002-12-21. Retrieved 2006-10-15. - includes picture of Teicoplanin's structure.

doi.org

Reynolds PE (November 1989). "Structure, biochemistry and mechanism of action of glycopeptide antibiotics". European Journal of Clinical Microbiology & Infectious Diseases. 8 (11): 943–950. doi:10.1007/BF01967563. PMID 2532132. S2CID 21551939.
Vimberg V (November 2021). "Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?". Pharmaceuticals (Basel, Switzerland). 14 (12): 1227. doi:10.3390/ph14121227. PMC 8708781. PMID 34959628.
Parenti F, Beretta G, Berti M, Arioli V (April 1978). "Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties". The Journal of Antibiotics. 31 (4): 276–83. doi:10.7164/antibiotics.31.276. PMID 659325.
Trautmann M, Wiedeck H, Ruhnke M, Oethinger M, Marre R (1994). "Teicoplanin: 10 years of clinical experience". Infection. 22 (6): 430–6. doi:10.1007/BF01715507. PMID 7698846.
Glupczynski Y, Lagast H, Van der Auwera P, Thys JP, Crokaert F, Yourassowsky E, et al. (January 1986). "Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria". Antimicrobial Agents and Chemotherapy. 29 (1): 52–7. doi:10.1128/AAC.29.1.52. PMC 180363. PMID 2942100.
Yushchuk O, Ostash B, Truman AW, Marinelli F, Fedorenko V (April 2020). "Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes". Applied Microbiology and Biotechnology. 104 (8): 3279–3291. doi:10.1007/s00253-020-10436-y. PMID 32076781. S2CID 211170874.
Campoli-Richards DM, Brogden RN, Faulds D (September 1990). "Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 40 (3): 449–486. doi:10.2165/00003495-199040030-00007. PMID 2146108. S2CID 195699141.
Quan M, Zhang X, Fang Q, Lv X, Wang X, Zong Z (July 2024). "Fighting against Clostridioides difficile infection: Current medications". International Journal of Antimicrobial Agents. 64 (1): 107198. doi:10.1016/j.ijantimicag.2024.107198. PMID 38734214.
Stabholz Y, Paul M (January 2024). "The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis". Clinical Microbiology and Infection. 30 (1): 51–58. doi:10.1016/j.cmi.2023.09.002. PMID 37690610.
de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. (October 1992). "Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea". Antimicrobial Agents and Chemotherapy. 36 (10): 2192–2196. doi:10.1128/AAC.36.10.2192. PMC 245474. PMID 1444298.
Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vékey K, et al. (August 1992). "Teicoplanin metabolism in humans". Antimicrobial Agents and Chemotherapy. 36 (8): 1744–1749. doi:10.1128/AAC.36.8.1744. PMC 192040. PMID 1416858.
Wang Y, Yao F, Chen S, Ouyang X, Lan J, Wu Z, et al. (2023). "Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type". Drug Design, Development and Therapy. 17: 2259–2271. doi:10.2147/DDDT.S413662. PMC 10404122. PMID 37546521.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, Gopalan D, Kulkarni S, et al. (September 2020). "Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements". Life Sciences. 256: 117883. doi:10.1016/j.lfs.2020.117883. PMC 7263255. PMID 32497632.
Geibel C, Olfert M, Knappe C, Serafimov K, Lämmerhofer M (February 2023). "Branched medium-chain fatty acid profiling and enantiomer separation of anteiso-forms of teicoplanin fatty acyl side chain RS3 using UHPLC-MS/MS with polysaccharide columns". Journal of Pharmaceutical and Biomedical Analysis. 224: 115162. doi:10.1016/j.jpba.2022.115162. PMID 36423498. S2CID 253529204.
Jung HM, Jeya M, Kim SY, Moon HJ, Kumar Singh R, Zhang YW, et al. (September 2009). "Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives". Applied Microbiology and Biotechnology. 84 (3): 417–428. doi:10.1007/s00253-009-2107-4. PMID 19609520. S2CID 45038487.
Heydorn A, Petersen BO, Duus JO, Bergmann S, Suhr-Jessen T, Nielsen J (March 2000). "Biosynthetic studies of the glycopeptide teicoplanin by (1)H and (13)C NMR". The Journal of Biological Chemistry. 275 (9): 6201–6206. doi:10.1074/jbc.275.9.6201. PMID 10692413.
Li TL, Huang F, Haydock SF, Mironenko T, Leadlay PF, Spencer JB (January 2004). "Biosynthetic gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and the key acyltransferase". Chemistry & Biology. 11 (1): 107–119. doi:10.1016/j.chembiol.2004.01.001. PMID 15113000.
Kaniusaite M, Tailhades J, Kittilä T, Fage CD, Goode RJ, Schittenhelm RB, et al. (January 2021). "Understanding the early stages of peptide formation during the biosynthesis of teicoplanin and related glycopeptide antibiotics". The FEBS Journal. 288 (2): 507–529. doi:10.1111/febs.15350. PMID 32359003. S2CID 218481859.
Kahne D, Leimkuhler C, Lu W, Walsh C (February 2005). "Glycopeptide and lipoglycopeptide antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
Kittilä T, Kittel C, Tailhades J, Butz D, Schoppet M, Büttner A, et al. (September 2017). "Halogenation of glycopeptide antibiotics occurs at the amino acid level during non-ribosomal peptide synthesis". Chemical Science. 8 (9): 5992–6004. doi:10.1039/C7SC00460E. PMC 5620994. PMID 28989629.
Haslinger K, Peschke M, Brieke C, Maximowitsch E, Cryle MJ (May 2015). "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis". Nature. 521 (7550): 105–109. Bibcode:2015Natur.521..105H. doi:10.1038/nature14141. PMID 25686610. S2CID 4466657.
Peschke M, Brieke C, Cryle MJ (October 2016). "F-O-G Ring Formation in Glycopeptide Antibiotic Biosynthesis is Catalysed by OxyE". Scientific Reports. 6 (1): 35584. Bibcode:2016NatSR...635584P. doi:10.1038/srep35584. PMC 5067714. PMID 27752135.
Kaplan J, Korty BD, Axelsen PH, Loll PJ (May 2001). "The role of sugar residues in molecular recognition by vancomycin". Journal of Medicinal Chemistry. 44 (11): 1837–1840. doi:10.1021/jm0005306. PMID 11356118.
Yushchuk O, Ostash B, Pham TH, Luzhetskyy A, Fedorenko V, Truman AW, et al. (August 2016). "Characterization of the Post-Assembly Line Tailoring Processes in Teicoplanin Biosynthesis". ACS Chemical Biology. 11 (8): 2254–2264. doi:10.1021/acschembio.6b00018. PMID 27285718.
Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, et al. (2022). "Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L". Frontiers in Microbiology. 13: 884034. doi:10.3389/fmicb.2022.884034. PMC 9096618. PMID 35572668.
Huang J, Ma Q, Su Z, Cheng X (October 2024). "Advancements in the Development of Anti-SARS-CoV-2 Therapeutics". International Journal of Molecular Sciences. 25 (19): 10820. doi:10.3390/ijms251910820. PMC 11477007. PMID 39409149.

europa.eu

ema.europa.eu

Human Medicines Evaluation Division (10 December 2020). "Active substance: teicoplanin" (PDF). List of nationally authorised medicinal products. European Medicines Agency.

harvard.edu

ui.adsabs.harvard.edu

Haslinger K, Peschke M, Brieke C, Maximowitsch E, Cryle MJ (May 2015). "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis". Nature. 521 (7550): 105–109. Bibcode:2015Natur.521..105H. doi:10.1038/nature14141. PMID 25686610. S2CID 4466657.
Peschke M, Brieke C, Cryle MJ (October 2016). "F-O-G Ring Formation in Glycopeptide Antibiotic Biosynthesis is Catalysed by OxyE". Scientific Reports. 6 (1): 35584. Bibcode:2016NatSR...635584P. doi:10.1038/srep35584. PMC 5067714. PMID 27752135.

nih.gov

pubmed.ncbi.nlm.nih.gov

Reynolds PE (November 1989). "Structure, biochemistry and mechanism of action of glycopeptide antibiotics". European Journal of Clinical Microbiology & Infectious Diseases. 8 (11): 943–950. doi:10.1007/BF01967563. PMID 2532132. S2CID 21551939.
Vimberg V (November 2021). "Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?". Pharmaceuticals (Basel, Switzerland). 14 (12): 1227. doi:10.3390/ph14121227. PMC 8708781. PMID 34959628.
Parenti F, Beretta G, Berti M, Arioli V (April 1978). "Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties". The Journal of Antibiotics. 31 (4): 276–83. doi:10.7164/antibiotics.31.276. PMID 659325.
Trautmann M, Wiedeck H, Ruhnke M, Oethinger M, Marre R (1994). "Teicoplanin: 10 years of clinical experience". Infection. 22 (6): 430–6. doi:10.1007/BF01715507. PMID 7698846.
Glupczynski Y, Lagast H, Van der Auwera P, Thys JP, Crokaert F, Yourassowsky E, et al. (January 1986). "Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria". Antimicrobial Agents and Chemotherapy. 29 (1): 52–7. doi:10.1128/AAC.29.1.52. PMC 180363. PMID 2942100.
Yushchuk O, Ostash B, Truman AW, Marinelli F, Fedorenko V (April 2020). "Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes". Applied Microbiology and Biotechnology. 104 (8): 3279–3291. doi:10.1007/s00253-020-10436-y. PMID 32076781. S2CID 211170874.
Campoli-Richards DM, Brogden RN, Faulds D (September 1990). "Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 40 (3): 449–486. doi:10.2165/00003495-199040030-00007. PMID 2146108. S2CID 195699141.
Quan M, Zhang X, Fang Q, Lv X, Wang X, Zong Z (July 2024). "Fighting against Clostridioides difficile infection: Current medications". International Journal of Antimicrobial Agents. 64 (1): 107198. doi:10.1016/j.ijantimicag.2024.107198. PMID 38734214.
Stabholz Y, Paul M (January 2024). "The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis". Clinical Microbiology and Infection. 30 (1): 51–58. doi:10.1016/j.cmi.2023.09.002. PMID 37690610.
de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. (October 1992). "Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea". Antimicrobial Agents and Chemotherapy. 36 (10): 2192–2196. doi:10.1128/AAC.36.10.2192. PMC 245474. PMID 1444298.
Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vékey K, et al. (August 1992). "Teicoplanin metabolism in humans". Antimicrobial Agents and Chemotherapy. 36 (8): 1744–1749. doi:10.1128/AAC.36.8.1744. PMC 192040. PMID 1416858.
Wang Y, Yao F, Chen S, Ouyang X, Lan J, Wu Z, et al. (2023). "Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type". Drug Design, Development and Therapy. 17: 2259–2271. doi:10.2147/DDDT.S413662. PMC 10404122. PMID 37546521.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, Gopalan D, Kulkarni S, et al. (September 2020). "Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements". Life Sciences. 256: 117883. doi:10.1016/j.lfs.2020.117883. PMC 7263255. PMID 32497632.
Geibel C, Olfert M, Knappe C, Serafimov K, Lämmerhofer M (February 2023). "Branched medium-chain fatty acid profiling and enantiomer separation of anteiso-forms of teicoplanin fatty acyl side chain RS3 using UHPLC-MS/MS with polysaccharide columns". Journal of Pharmaceutical and Biomedical Analysis. 224: 115162. doi:10.1016/j.jpba.2022.115162. PMID 36423498. S2CID 253529204.
Jung HM, Jeya M, Kim SY, Moon HJ, Kumar Singh R, Zhang YW, et al. (September 2009). "Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives". Applied Microbiology and Biotechnology. 84 (3): 417–428. doi:10.1007/s00253-009-2107-4. PMID 19609520. S2CID 45038487.
Heydorn A, Petersen BO, Duus JO, Bergmann S, Suhr-Jessen T, Nielsen J (March 2000). "Biosynthetic studies of the glycopeptide teicoplanin by (1)H and (13)C NMR". The Journal of Biological Chemistry. 275 (9): 6201–6206. doi:10.1074/jbc.275.9.6201. PMID 10692413.
Li TL, Huang F, Haydock SF, Mironenko T, Leadlay PF, Spencer JB (January 2004). "Biosynthetic gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and the key acyltransferase". Chemistry & Biology. 11 (1): 107–119. doi:10.1016/j.chembiol.2004.01.001. PMID 15113000.
Kaniusaite M, Tailhades J, Kittilä T, Fage CD, Goode RJ, Schittenhelm RB, et al. (January 2021). "Understanding the early stages of peptide formation during the biosynthesis of teicoplanin and related glycopeptide antibiotics". The FEBS Journal. 288 (2): 507–529. doi:10.1111/febs.15350. PMID 32359003. S2CID 218481859.
Kahne D, Leimkuhler C, Lu W, Walsh C (February 2005). "Glycopeptide and lipoglycopeptide antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
Kittilä T, Kittel C, Tailhades J, Butz D, Schoppet M, Büttner A, et al. (September 2017). "Halogenation of glycopeptide antibiotics occurs at the amino acid level during non-ribosomal peptide synthesis". Chemical Science. 8 (9): 5992–6004. doi:10.1039/C7SC00460E. PMC 5620994. PMID 28989629.
Haslinger K, Peschke M, Brieke C, Maximowitsch E, Cryle MJ (May 2015). "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis". Nature. 521 (7550): 105–109. Bibcode:2015Natur.521..105H. doi:10.1038/nature14141. PMID 25686610. S2CID 4466657.
Peschke M, Brieke C, Cryle MJ (October 2016). "F-O-G Ring Formation in Glycopeptide Antibiotic Biosynthesis is Catalysed by OxyE". Scientific Reports. 6 (1): 35584. Bibcode:2016NatSR...635584P. doi:10.1038/srep35584. PMC 5067714. PMID 27752135.
Kaplan J, Korty BD, Axelsen PH, Loll PJ (May 2001). "The role of sugar residues in molecular recognition by vancomycin". Journal of Medicinal Chemistry. 44 (11): 1837–1840. doi:10.1021/jm0005306. PMID 11356118.
Yushchuk O, Ostash B, Pham TH, Luzhetskyy A, Fedorenko V, Truman AW, et al. (August 2016). "Characterization of the Post-Assembly Line Tailoring Processes in Teicoplanin Biosynthesis". ACS Chemical Biology. 11 (8): 2254–2264. doi:10.1021/acschembio.6b00018. PMID 27285718.
Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, et al. (2022). "Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L". Frontiers in Microbiology. 13: 884034. doi:10.3389/fmicb.2022.884034. PMC 9096618. PMID 35572668.
Huang J, Ma Q, Su Z, Cheng X (October 2024). "Advancements in the Development of Anti-SARS-CoV-2 Therapeutics". International Journal of Molecular Sciences. 25 (19): 10820. doi:10.3390/ijms251910820. PMC 11477007. PMID 39409149.

ncbi.nlm.nih.gov

Vimberg V (November 2021). "Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?". Pharmaceuticals (Basel, Switzerland). 14 (12): 1227. doi:10.3390/ph14121227. PMC 8708781. PMID 34959628.
Glupczynski Y, Lagast H, Van der Auwera P, Thys JP, Crokaert F, Yourassowsky E, et al. (January 1986). "Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria". Antimicrobial Agents and Chemotherapy. 29 (1): 52–7. doi:10.1128/AAC.29.1.52. PMC 180363. PMID 2942100.
de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. (October 1992). "Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea". Antimicrobial Agents and Chemotherapy. 36 (10): 2192–2196. doi:10.1128/AAC.36.10.2192. PMC 245474. PMID 1444298.
Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vékey K, et al. (August 1992). "Teicoplanin metabolism in humans". Antimicrobial Agents and Chemotherapy. 36 (8): 1744–1749. doi:10.1128/AAC.36.8.1744. PMC 192040. PMID 1416858.
Wang Y, Yao F, Chen S, Ouyang X, Lan J, Wu Z, et al. (2023). "Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type". Drug Design, Development and Therapy. 17: 2259–2271. doi:10.2147/DDDT.S413662. PMC 10404122. PMID 37546521.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, Gopalan D, Kulkarni S, et al. (September 2020). "Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements". Life Sciences. 256: 117883. doi:10.1016/j.lfs.2020.117883. PMC 7263255. PMID 32497632.
Kittilä T, Kittel C, Tailhades J, Butz D, Schoppet M, Büttner A, et al. (September 2017). "Halogenation of glycopeptide antibiotics occurs at the amino acid level during non-ribosomal peptide synthesis". Chemical Science. 8 (9): 5992–6004. doi:10.1039/C7SC00460E. PMC 5620994. PMID 28989629.
Peschke M, Brieke C, Cryle MJ (October 2016). "F-O-G Ring Formation in Glycopeptide Antibiotic Biosynthesis is Catalysed by OxyE". Scientific Reports. 6 (1): 35584. Bibcode:2016NatSR...635584P. doi:10.1038/srep35584. PMC 5067714. PMID 27752135.
Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, et al. (2022). "Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L". Frontiers in Microbiology. 13: 884034. doi:10.3389/fmicb.2022.884034. PMC 9096618. PMID 35572668.
Huang J, Ma Q, Su Z, Cheng X (October 2024). "Advancements in the Development of Anti-SARS-CoV-2 Therapeutics". International Journal of Molecular Sciences. 25 (19): 10820. doi:10.3390/ijms251910820. PMC 11477007. PMID 39409149.

sciencedirect.com

Murray BE, Arias CA, Nannini EC (2014). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8 ed.). Philadelphia, PA: Elsevier Health Sciences. p. 377. ISBN 978-1-4557-4801-3.

semanticscholar.org

api.semanticscholar.org

Reynolds PE (November 1989). "Structure, biochemistry and mechanism of action of glycopeptide antibiotics". European Journal of Clinical Microbiology & Infectious Diseases. 8 (11): 943–950. doi:10.1007/BF01967563. PMID 2532132. S2CID 21551939.
Yushchuk O, Ostash B, Truman AW, Marinelli F, Fedorenko V (April 2020). "Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes". Applied Microbiology and Biotechnology. 104 (8): 3279–3291. doi:10.1007/s00253-020-10436-y. PMID 32076781. S2CID 211170874.
Campoli-Richards DM, Brogden RN, Faulds D (September 1990). "Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 40 (3): 449–486. doi:10.2165/00003495-199040030-00007. PMID 2146108. S2CID 195699141.
Geibel C, Olfert M, Knappe C, Serafimov K, Lämmerhofer M (February 2023). "Branched medium-chain fatty acid profiling and enantiomer separation of anteiso-forms of teicoplanin fatty acyl side chain RS3 using UHPLC-MS/MS with polysaccharide columns". Journal of Pharmaceutical and Biomedical Analysis. 224: 115162. doi:10.1016/j.jpba.2022.115162. PMID 36423498. S2CID 253529204.
Jung HM, Jeya M, Kim SY, Moon HJ, Kumar Singh R, Zhang YW, et al. (September 2009). "Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives". Applied Microbiology and Biotechnology. 84 (3): 417–428. doi:10.1007/s00253-009-2107-4. PMID 19609520. S2CID 45038487.
Kaniusaite M, Tailhades J, Kittilä T, Fage CD, Goode RJ, Schittenhelm RB, et al. (January 2021). "Understanding the early stages of peptide formation during the biosynthesis of teicoplanin and related glycopeptide antibiotics". The FEBS Journal. 288 (2): 507–529. doi:10.1111/febs.15350. PMID 32359003. S2CID 218481859.
Haslinger K, Peschke M, Brieke C, Maximowitsch E, Cryle MJ (May 2015). "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis". Nature. 521 (7550): 105–109. Bibcode:2015Natur.521..105H. doi:10.1038/nature14141. PMID 25686610. S2CID 4466657.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

toku-e.com

"Teicoplanin Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). TOKU-E.

web.archive.org

Gilpin M, Milner P (1997). "Resisting changes -- Over the past 40 years the glycopeptide antibiotics have played a crucial role in treating bacterial infections. But how long can it continue?". Royal Society of Chemistry. Archived from the original on 2002-12-21. Retrieved 2006-10-15. - includes picture of Teicoplanin's structure.